November 20th 2024
Melt Pharmaceuticals announced positive results from its Phase 3 study of MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. The results support a regulatory submission, with potential to revolutionize sedation practices in various medical specialties.
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Advancing Treatment in Neovascular Retinal Disease with Novel Therapies: Insights and Strategies from Latest Real-World and Clinical Data
View More
Rapid Reviews in Retina™: Emerging Updates from Fall 2023 – Addressing the Wealth of New Data in Treatments for nAMD and DME
View More
(CME) Stratifying the Spectrum of Care in Glaucoma Management – Advancing Treatment with a Vast Armamentarium
View More
(CME) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(COPE) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(CME) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(COPE) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(CME) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
(COPE) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (CME Credit)
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (COPE Credit)
View More
SimulatED™: Applying Advanced Treatment for nAMD & DME - Simulating New Strategies for Clinical Management
View More
EnVision Summit
February 14-17, 2025
Register Now!
Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
March 16, 2025
Register Now!
Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care
View More
Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)
View More
Surv.AI Says: Real-World Insights into Patient Burden & Evolving Strategies in nAMD and DME (COPE Credit)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (COPE Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)
View More
Presbyopic lens exchange for high myopia problematic
October 15th 2006Alicante, Spain-While one segment of the ophthalmic community sees presbyopic lens exchange for patients with high myopia as a promising, safe technique leading to good improvements in visual acuity, another segment does not, stating that the risk of retinal detachment and other complications related to the surgery are just too high, according to Jorge L. Alio, MD.
Read More
Safety favorable with pediatric primary IOL implantation
October 15th 2006Charleston, SC-Pediatric cataract surgery with IOL implantation and primary posterior capsulectomy plus vitrectomy is associated with a satisfactory outcome, especially in children operated on after their first birthday, said Rupal H. Trivedi, MD, MSCR.
Read More
Late optic calcification in hydrophilic acrylic lens poses vision risks
October 15th 2006Salt Lake City-Failure to recognize late opacification of the MemoryLens IOL (CIBA Vision) as a cause for vision problems can have potentially negative consequences, including unnecessary surgery and complications secondary to those procedures, said Jonathan G. Haymore, MD.
Read More
AMO's Tecnis CL replaces company's other silicone IOL models
October 4th 2006Advanced Medical Optics Inc. (AMO) launched its Tecnis CL silicone IOL, which reduces spherical aberrations, improves functional vision, and improves night-driving simulator performance. This IOL replaces the company’s Z9000 and Z9001 Tecnis silicone IOL models.
Read More
Could a multifocal IOL be the answer to patients' visual needs?
October 1st 2006The Tecnis multifocal IOL (Advanced Medical Optics) has been shown to be highly effective for patients with different clinical needs, such as in patients undergoing cataract surgery and IOL implantation, those with presbyopia, and in those with hyperopia. Three studies presented at the annual meeting of the American Society of Cataract and Refractive Surgery reported the results with this IOL.
Read More
Can cataract/refractive surgeons upgrade their customer service?
October 1st 2006Pleasanton, CA-Certain elements are key to building a successful lenticular refractive practice, according to Shareef Mahdavi, BA. While technology will continue to evolve, success with implants will likewise require physicians to evolve their approaches to the business side of refractive surgery, namely, upgrading their customer service.
Read More
Combination treatment may improve keratoconus/post-LASIK ectasia
October 1st 2006Minneapolis, MN-Early results are promising regarding the potential role of conductive keratoplasty (CK, Refractec) as an additional tool to improve vision outcomes in eyes with keratoconus or post-LASIK ectasia treated with corneal implants (Intacs, Addition Technology), said Jason K. Darlington, MD.
Read More
Aggressive treatment aids in corneal transplant rejection
October 1st 2006Cincinnati-"Regardless of whether we are talking about full-thickness transplants or endothelial transplants, corneal transplant rejection is the leading cause of graft failure," said Edward J. Holland, MD, director, Cornea and External Diseases, Cincinnati Eye Institute, Cincinnati.
Read More
Could a multifocal IOL be the answer to patients' visual needs?
October 1st 2006The Tecnis multifocal IOL (Advanced Medical Optics) has been shown to be highly effective for patients with different clinical needs, such as in patients undergoing cataract surgery and IOL implantation, those with presbyopia, and in those with hyperopia. Three studies presented at the annual meeting of the American Society of Cataract and Refractive Surgery reported the results with this IOL.
Read More
Accommodating IOL design modification reduces PCO
October 1st 2006Los Angeles-Preliminary results from a prospective study of patients with the crystalens square edge (SE) accommodating IOL (eyeonics) implanted suggest modification of the original optic edge design has been effective for reducing the development of posterior capsule opacification (PCO) and without causing an increase in visual quality-related complaints, according to D. Michael Colvard, MD.
Read More
Improving blepharoplasty results with careful observation
October 1st 2006Baltimore-Surgical results for patients requesting a blepharoplasty can be improved if the surgeon carefully examines individuals for coexisting diagnoses, pre-existing asymmetries, brow position, and lower eyelid malposition, explained Shannath L. Merbs, MD, PhD, FACS.
Read More
Tunnel creation examined as another femtosecond laser application
October 1st 2006Baltimore-Tunnel creation for placement of corneal implants (Intacs, Addition Technology) in eyes with corneal ectasia is a promising new use for the femtosecond laser (IntraLase FS, IntraLase), according to Alisa Kim, MD.
Read More
Botulinum toxin gains popularity for variety of disorders
September 15th 2006The use of botulinum toxin by ophthalmologists to treat a variety of disorders has exploded over the past several years. It has highlighted many issues of interest, including off-label use, supply charges, and cosmetic indications. All of these have important implications for coding, billing, and reimbursement.
Read More
Initial experience good with accommodating IOL
September 15th 2006San Francisco-In an initial analysis, the Synchrony dual-optic single-piece IOL (Visiogen) performed well. The visual results were good, there were no major complications and no glare or halos after implantation, and patient satisfaction was high, according to George Beiko, BM, BCh, FRCS.
Read More
Clear corneal incisions and silicon IOLs new endophthalmitis risk factors
September 11th 2006Clear corneal incisions and silicon IOLs are new risk factors in post-cataract surgery endophthalimitis, Peter Barry revealed in the first presentation of the full ESCRS endophthalmitis study results.
Read More
Blue light-blocking IOLs unnecessary
September 10th 2006There is no current proof that blocking blue wavelengths guarantees retinal protection and, couple this with the fact that blocking this form of light causes an actual loss in visual quality, Alessandro Franchini MD, suggests we concentrate our efforts on blocking UV and violet radiations instead.
Read More
Good pseudoaccommodation with MICS lens at one year
September 9th 2006The new MICS lens (Ioltech-Zeiss) is appropriate for the correction of intermediate vision in pseudophakia, according to Carlos Verges, Jorge Cazal and Marc Menezo of the Department of Ophthalmology, Institut Universitari Dexeus, Barcelona, Spain.
Read More
Drainage devices useful for refractory disease
September 1st 2006Fort Lauderdale, FL-The B?rveldt-250 mm2 Glaucoma Implant (Advanced Medical Optics) seems to be more effective at lowering IOP than the Ahmed S2 Glaucoma Valve (New World Medical Inc.) in adult patients with refractory glaucoma. However, regardless of which of the devices is implanted, the preoperative IOP is a risk factor for eventual failure, according to Darrell WuDunn, MD, PhD, and colleagues, who presented their findings at the annual meeting of the Association for Research in Vision and Ophthalmology.
Read More
Lenstec sales office opens in Barcelona
September 1st 2006St. Petersburg, FL-Lenstec Inc. opened a new Barcelona sales office to help the company meet growing European demand for its lens implants and devices used in cataract and refractive surgery. With a sales and marketing office in Yorkshire, England, this move expands Lenstec's European operations.
Read More
More than 50,000 crystalenses implanted
September 1st 2006Aliso Viejo, CA-Since FDA approval in 2003, more than 50,000 crystalens accommodating IOLs (eyeonics) have been implanted worldwide. Of these, 17,000 implants were with the crystalens SE second-generation lens (introduced in 2005), the company said in a prepared statement.
Read More
Modified glaucoma value reduces outflow resistance
September 1st 2006Fort Lauderdale, FL-A modified glaucoma valve made of a porous polymer material reduced outflow resistance in tests conducted in an animal model. The reduced resistance should in turn result in improved control of IOP over conventional implants, explained R. Rand Allingham, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Read More
SLT may be useful as primary glaucoma therapy
September 1st 2006London, Ontario-During at least the first 12 months after treatment initiation, selective laser trabeculoplasty (SLT) and latanoprost 0.005% (Xalatan, Pfizer) are associated with equivalent efficacy and safety profiles when used as primary therapy for newly diagnosed open-angle glaucoma or ocular hypertension, according to the results of a prospective, multicenter, parallel comparison, clinical trial conducted by researchers at Ivey Eye Institute, University of Western Ontario, London.
Read More